koreabiomed.com·3 min read·hard
RSV prevention market broadens as focus expands to high-risk children entering a 2nd season
✦AI Summary
The market for RSV prevention is expanding, with a focus on high-risk children entering their second season. While products like Sanofi's Beyfortus and MSD's Enflonsia target infants, Beyfortus currently holds a unique position for high-risk children in their second season.
As the market for respiratory syncytial virus (RSV) preventive antibody injections for infants and young children continues to expand, greater attention is shifting toward prevention strategies that cover not only infants entering their first RSV season but also high-risk children under the age of two entering their second season.
healthbusinessscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in